Publications by authors named "E S G Stroes"
Plasma proteomics improves prediction of coronary plaque progression.
Eur Heart J Cardiovasc Imaging
December 2024
Aims: Coronary computed tomography angiography (CCTA) offers detailed imaging of plaque burden and composition, with plaque progression being a key determinant of future cardiovascular events. As repeated CCTA scans are burdensome and costly, there is a need for non-invasive identification of plaque progression. This study evaluated whether combining proteomics with traditional risk factors can detect patients at risk for accelerated plaque progression.
View Article and Find Full Text PDFEstimating inflammatory risk in atherosclerotic cardiovascular disease: plaque over plasma?
Eur Heart J Cardiovasc Imaging
December 2024
Inflammation is an important driver of disease in the context of atherosclerosis, and several landmark trials have shown that targeting inflammatory pathways can reduce cardiovascular event rates. However, the high cost and potentially serious adverse effects of anti-inflammatory therapies necessitate more precise patient selection. Traditional biomarkers of inflammation, such as high-sensitivity C-reactive protein (hsCRP), show an association with cardiovascular risk on a population level, but do not have specificity for local plaque inflammation.
View Article and Find Full Text PDFArticle Synopsis
- The study focuses on Tc-fucoidan, a compound derived from brown algae, which targets P-selectin for early identification of thrombosis.
- In the safety assessment involving ten healthy volunteers, Tc-fucoidan was well tolerated with no adverse effects and demonstrated reliable uptake in human thrombi in gamma counting experiments.
- Although the results showed potential for imaging thrombi in certain cases, the overall findings do not support further clinical use of Tc-fucoidan for diagnosing deep vein thrombosis (DVT), suggesting exploration of alternative P-selectin tracers instead.
Importance: Elevated lipoprotein(a) increases the risk of atherosclerotic cardiovascular disease (ASCVD) and aortic stenosis.
Objective: To evaluate the effects of zerlasiran, a small-interfering RNA targeting hepatic synthesis of apolipoprotein(a), on lipoprotein(a) serum concentration.
Design, Setting, And Participants: A multicenter trial in patients with stable ASCVD with serum lipoprotein(a) concentrations greater than or equal to 125 nmol/L at 26 sites in Europe and South Africa between January 3, 2023, and April 27, 2023, with last follow-up on July 1, 2024.